tazarotene 0.0005 MG/MG Topical Gel [Tazorac]

Verify with CMS →

tazarotene

RxCUI: 212437

Important: Drug coverage and costs vary by plan and location. Verify coverage directly with your Medicare plan before filling a prescription. This is informational data only and should not replace advice from your healthcare provider or pharmacist.
0%
Plan Coverage
2
Plans Covering
T1
Avg Tier
100%
Prior Auth Required

What the CMS Formulary Data Shows for tazarotene 0.0005 MG/MG Topical Gel [Tazorac]

Per the CMS 2026 Part D formulary file, tazarotene 0.0005 MG/MG Topical Gel [Tazorac] (RxNorm concept RXCUI 212437, generic name tazarotene) appears on 1 distinct formulary file spanning 2 Medicare Part D plan offerings - 0% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 1, with a cross-plan average of Tier 1.

Real-world access to tazarotene 0.0005 MG/MG Topical Gel [Tazorac] depends on utilization management as much as tier placement: 100% of covering formularies require prior authorization. 0% require step therapy. 100% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 4,869 Part D beneficiaries filled tazarotene 0.0005 MG/MG Topical Gel [Tazorac] in 2023, with total plan-and-beneficiary spending of $2,710,202 and an average per-beneficiary annual cost of $556.62. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry tazarotene 0.0005 MG/MG Topical Gel [Tazorac] today.

Coverage Details

Formularies covering
1
Plans covering
2
Coverage rate
0%
Tier range
Tier 1, Preferred Generic
Average tier
Tier 1, Preferred Generic

Restrictions

Prior authorization required
100% of formularies
Step therapy required
0% of formularies
Quantity limits
100% of formularies

2023 Medicare Spending

Beneficiaries
4,869
Total spending
$2,710,202
Avg per beneficiary
$556.62

Tier Distribution Across Plans

2 plans
Tier 1, Preferred Generic

Medicare Advantage Plans (MA-PD) Covering tazarotene 0.0005 MG/MG Topical Gel [Tazorac]

2 Medicare Advantage plans with Part D drug coverage include this drug.

Plan Insurer Tier PA Premium States
Hamaspik Medicare Choice (HMO D-SNP) HAMASPIK, INC. T1 Yes $0 NY
Hamaspik Medicare Select (HMO D-SNP) HAMASPIK, INC. T1 Yes $34.50 NY

Frequently Asked Questions

Is tazarotene 0.0005 MG/MG Topical Gel [Tazorac] covered by Medicare Part D?

Yes, tazarotene 0.0005 MG/MG Topical Gel [Tazorac] is covered by 2 Medicare Part D plans (0% of all Part D formularies).

What tier is tazarotene 0.0005 MG/MG Topical Gel [Tazorac] on Medicare Part D plans?

tazarotene 0.0005 MG/MG Topical Gel [Tazorac] averages Tier 1 across Part D plans, ranging from Tier 1 to Tier 1.

Does tazarotene 0.0005 MG/MG Topical Gel [Tazorac] require prior authorization?

100% of Part D formularies require prior authorization for tazarotene 0.0005 MG/MG Topical Gel [Tazorac]. Step therapy: 0%. Quantity limits: 100%.

How much does Medicare spend on tazarotene 0.0005 MG/MG Topical Gel [Tazorac]?

In 2023, total Medicare Part D spending on tazarotene 0.0005 MG/MG Topical Gel [Tazorac] was $2,710,202, covering 4,869 beneficiaries. The average spend per beneficiary was $556.62.

Data sourced from the Centers for Medicare & Medicaid Services (CMS). See our methodology for details. Retrieved and formatted by PlainMedicare Editorial